NR1H4 and metabolic dysfunction-associated steatohepatitis: According to Zhang et al. study, administration of an FXR agonist, WAY-362450, was associated with a marked reduction of inflammatory cell infiltration in a mouse model of non-alcoholic steatohepatitis (Zhang et al., 2009 ▶).